MSM
Methylsulfonylmethane · Dimethyl Sulfone · Organic Sulfur Donor
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The evidence sits at preliminary. For knee osteoarthritis, the two most-cited placebo-controlled trials are small and short. Kim 2006 (50 patients, 6 g/day, 12 weeks) reported improved WOMAC pain and function versus placebo, and Debbi 2011 (49 patients, 3.375 g/day, 12 weeks) found a statistically significant function benefit (p=0.04) but only a trend for pain (p=0.08), with the authors themselves calling the improvements small and of uncertain clinical significance. The 2011 Brien meta-analysis pooling DMSO and MSM trials concluded neither was clinically effective for osteoarthritis pain. For exercise recovery, Kalman 2012 was a pilot (trends only) and Withee 2017 (half-marathon runners, 3 g/day) found no reduction in oxidative stress or muscle damage and only clinically-but-not-statistically-significant pain attenuation. Small samples, short durations, and low methodological weight across the literature justify a 2, not the current 3. Other marketed claims (allergy, skin, general inflammation) rest on weaker single studies.
- FDA
- Legal supplement (DSHEA); GRAS food
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Very well tolerated short term; mild GI upset most common, long-term and pregnancy data thin, and a theoretical blood-thinning note warrants pre-surgery and anticoagulant caution.
MSM, methylsulfonylmethane, is a naturally occurring sulfur compound and the main metabolite of DMSO. It turns up in trace amounts across the diet, in fruits, vegetables, grains, coffee, tea, beer, wine, and cow's milk, and it circulates through the environmental sulfur cycle. It supplies sulfur that the body uses for connective tissue and for making the antioxidant glutathione. The honest headline is modest: small, short randomized trials suggest a mild benefit for knee osteoarthritis pain and function, but systematic reviewers judge those trials low in quality and one pooled analysis found no clinically meaningful effect. It is very well tolerated, which is part of why it stays popular.
A sulfur donor with modest evidence for joint comfort and exercise recovery.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Combinations named above are how people use these compounds together, under names the community gave them. The combinations themselves have not been studied. Evidence for one compound is not evidence for a pair.
How it is supposed to work
Methylsulfonylmethane is a naturally-occurring organosulfur compound (dimethyl sulfone, (CH3)2SO2), the fully oxidized form of dimethyl sulfoxide (DMSO). The body produces it endogenously through gut bacterial metabolism of dietary sulfur compounds and through hepatic oxidation of DMSO. Trace amounts exist in milk, coffee, tea, and many vegetables, typical dietary intake is 2-6mg/day, far below supplemental doses. MSM supplements provide a concentrated source of bioavailable sulfur, which the body uses in three principal ways: as substrate for cysteine and methionine synthesis (essential sulfur amino acids), as a building block for glutathione (the major endogenous antioxidant), and as donor sulfur for the disulfide cross-links in collagen, keratin, elastin, and many enzymes. The sulfur in connective tissue matters: cartilage, ligament, and tendon contain substantially more sulfur per gram than soft tissue, and chondroitin sulfate (a glycosaminoglycan in joint matrix) is named for its sulfate content. The anti-inflammatory mechanism extends beyond simple sulfur donation. MSM modulates NF-kB inflammatory signaling, reduces pro-inflammatory cytokine production (IL-6, TNF-α), and stabilizes cell membranes against oxidative damage. In joint tissue, MSM appears to reduce inflammatory mediators while supporting glutathione regeneration in chondrocytes. The exercise recovery mechanism likely involves both reduced oxidative stress and stabilization of cell membranes against the inflammatory cascade of high-intensity exercise. The seasonal allergic rhinitis mechanism is less well-characterized but may involve mast cell stabilization and immunomodulation. Despite the chemical name resemblance, MSM does not cross-react with sulfa drug (sulfonamide) allergies, the chemistry is structurally different and the immunology is distinct.
How it is taken
The clinical dose range is wide: 1.5g/day at the lower end of joint protocols, 3-6g/day in most positive trials, with safety established up to 6g/day in long-term use. Divided dosing (typically twice daily) is preferred for steady-state plasma levels. Take with or without food, absorption is essentially complete regardless. Onset of joint effects is slow (4-12 weeks); exercise recovery effects accumulate over 7-28 days of consistent use. Effects fade gradually after discontinuation. MSM is well-tolerated long-term; cycling is not necessary. The form matters substantially: OptiMSM distilled material from clinical trials versus commodity crystalline material from unspecified sources represents a meaningful quality difference. Pre-surgical discontinuation (1-2 weeks before elective procedures) is reasonable given mild antiplatelet activity at high doses, though clinical bleeding events from MSM alone are rare.
- Joint OA standalone
- 3g twice daily for 8-12 weeks
- Joint combination
- 1500-3000mg MSM with glucosamine + chondroitin
- Exercise recovery
- 3g/day for 7-28 days pre-event
- Allergic rhinitis
- 2.6g/day during allergy season
- Form
- OptiMSM distilled preferred over crystalline
- Food state
- With or without food
- Time to effect
- Joint: 4-12 weeks. Recovery: 7-28 days.
- Pre-surgery
- Consider 1-2 week discontinuation before elective procedures
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
OptiMSM® (Bergstrom Nutrition)
The pharmaceutical-grade branded MSM used in essentially all major clinical trials of the past two decades. Distilled rather than crystallized, producing 99.7% pure MSM with substantially lower contamination than commodity crystalline forms. Tested under USP and Informed Sport standards. Most premium consumer brands license OptiMSM and disclose it on the label.
Crystalline MSM (Filtered)
Most commodity MSM is produced via crystallization rather than distillation, cheaper but with substantially higher risk of trace solvent contamination, heavy metals, and inconsistent purity. Many low-tier supplements use unspecified crystalline MSM. The 80% of MSM by volume on the market not from distilled sources.
MSM + Glucosamine + Chondroitin Combination
The classical "triple stack", Usha 2004 demonstrated superior outcomes for the combination versus glucosamine alone in knee OA. Common formulation in joint supplements; verify each component dose and OptiMSM disclosure. Synergistic mechanisms: substrate provision (glucosamine, chondroitin) + sulfur donor (MSM) + anti-inflammatory (all three).
MSM + Glucosamine Combination
Two-component formulations without chondroitin. The Usha 2004 foundational evidence used this specific combination. Acceptable for users who don't tolerate or want chondroitin.
Topical MSM Creams and Gels
MSM in transdermal preparations for joint pain, muscle soreness, and skin conditions. Modest evidence; mechanism may be local penetration plus anti-inflammatory activity. Often combined with menthol, capsaicin, or arnica. Pleasant adjunct to oral.
MSM Powder (Bulk)
Bulk MSM powder for high-dose protocols. Mixes with water (slight bitter taste); economical at therapeutic doses. Quality varies enormously, distilled OptiMSM versus commodity crystalline matters significantly. Verify source.
MSM Eye Drops
Marketed for eye health, cataract support, and floaters. Limited clinical evidence for ophthalmic applications. Conservative ophthalmology has not endorsed routine use. Sterility concerns with consumer eye drops require careful brand selection.
Who it works for, and who it does not
Knee osteoarthritis (standalone)
Kim 2006 and several smaller trials support MSM standalone at 3-6g/day for knee OA pain and function. Effect size moderate; substantially larger when combined with glucosamine and chondroitin. The classical joint use case.
Knee osteoarthritis (combination with glucosamine + chondroitin)
Usha 2004 demonstrated meaningful additive benefit. The combination is the dominant US consumer formulation. Most positive joint trials evaluate combinations rather than standalone components.
Exercise-induced muscle soreness and recovery
Pagonis 2014 (endurance) and Withee 2017 (resistance training) support MSM at 3g/day for 10-28 days pre-exercise reducing muscle soreness, fatigue, and inflammatory markers. Real but modest effect; not a substitute for adequate sleep, nutrition, and recovery time.
Seasonal allergic rhinitis
Barrager 2002 pilot evidence is encouraging but preliminary; larger trials have not consistently replicated. Reasonable trial for users who don't tolerate or prefer to avoid antihistamines.
General "joint wellness" in active adults
The mass-market preventive consumer use. Limited evidence for benefit in healthy joints. Most trials enroll established OA or athletic recovery contexts.
Inflammatory skin conditions
Some preliminary evidence for psoriasis, rosacea, and other inflammatory skin conditions through both oral and topical applications. Mechanistically plausible (sulfur amino acid donation, anti-inflammatory). Not yet established dermatology practice.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Glucosamine + Chondroitin
The Usha 2004 foundational evidence. The classical "joint triple stack." Mechanistically complementary: substrate provision (glucosamine, chondroitin) + sulfur donor (MSM) + multiple anti-inflammatory pathways.
Vitamin C
Vitamin C is cofactor for collagen synthesis; MSM provides sulfur substrate for disulfide cross-links in connective tissue. Mechanistically defensible co-supplementation in joint and connective tissue protocols.
Hyaluronic Acid
Different mechanisms but overlapping joint matrix support. Common combination in comprehensive joint formulations.
Collagen Peptides
Sulfur donor (MSM) supports collagen synthesis substrate (peptides). Common combination in skin and joint protocols.
Turmeric / Curcumin
Anti-inflammatory mechanism complement. Both have knee OA evidence at different effect sizes. Reasonable joint-protocol combination.
Quercetin
Mast cell stabilization mechanism complement for allergic rhinitis indication. Common allergy-protocol pairing.
Anticoagulants (warfarin, DOACs)
Mild antiplatelet activity at high doses. Most users tolerate combination but conservative practice is to discontinue 1-2 weeks before elective procedures.
Aspirin
Theoretical additive antiplatelet effect at high MSM doses. Clinical bleeding events rare; pre-surgical discontinuation reasonable.
Diabetes medications
Minimal documented interactions with diabetes medications. Some preliminary signal of mild glucose effects; monitor when initiating in diabetic patients.
What to look for on the label
Look for: OptiMSM® (Bergstrom Nutrition) explicitly disclosed on the label; distilled rather than crystalline production specified; third-party testing (NSF, USP, Informed Sport); reputable joint formulations that disclose OptiMSM in combination products (Doctor's Best, Pure Encapsulations, Thorne); explicit MSM dose disclosure rather than proprietary blends. Avoid: products that don't disclose OptiMSM or distillation source; cheap commodity MSM without third-party testing; combination products that obscure individual MSM dose; "MSM water" or other diluted formulations with subclinical effective dose.
Safety in detail
- Generally very well tolerated at studied doses (1.5-6g/day). Brien 2008 safety review found no serious adverse events across the supplement literature.
- Mild GI upset (nausea, diarrhea) is the most common side effect, particularly at high single doses; resolved by dividing dose.
- Headache and dermatologic effects (skin rash, mild itching) occur in a small minority of users; typically dose-related and reversible.
- Mild antiplatelet activity at high doses (>3g/day) is documented. Clinical bleeding events from MSM alone are rare; pre-surgical discontinuation 1-2 weeks before elective procedures is conservative practice.
- No documented hepatotoxicity at therapeutic doses. Sulfur metabolism does not produce hepatic stress.
- Sulfa allergy: MSM does NOT cause sulfa-allergy (sulfonamide) reactions. The chemistry is structurally different; the immunology is distinct. This is one of the most common misconceptions.
- Pregnancy and breastfeeding: limited systematic safety data. Endogenous MSM is present from dietary sources during pregnancy; supplemental doses not routinely recommended without OB-GYN guidance.
- Pediatric: limited safety data at supplement doses. Not routine pediatric supplementation.
- Drug interactions are minimal beyond the antiplatelet consideration. Generally tolerated alongside cardiovascular and metabolic medications.
What people get wrong
Often saidMSM cannot be taken by people with sulfa allergies.
ActuallyMSM does NOT cause sulfa allergy reactions. The chemistry is structurally distinct from sulfonamide drugs. Sulfa allergy is to the sulfonamide functional group; MSM has a sulfone group with different chemistry and different immunology. One of the most common misconceptions.
Often saidMSM rebuilds cartilage.
ActuallyThe substrate provision mechanism (sulfur donation for chondroitin sulfate synthesis) is plausible but the clinical effect appears modest. MSM appears more reliably anti-inflammatory than structurally rebuilding. The "rebuilds cartilage" framing overstates the trial-level evidence.
Often saidAll MSM products are equivalent.
ActuallyOptiMSM (distilled) and commodity crystalline MSM have substantially different purity profiles. Most positive clinical trials used OptiMSM. Source disclosure on the label matters; "MSM 1000mg" without source specification can be either.
Often saidHigher dose MSM produces dramatically better results.
ActuallyClinical trials cluster at 1.5-6g/day. Higher doses (>6g) have not been shown to produce proportionally better outcomes and may increase GI side effects without clear additional benefit.
Often saidMSM is a miracle cure for arthritis.
ActuallyMSM produces modest symptomatic improvement in joint pain trials, larger when combined with glucosamine and chondroitin. It is symptomatic management with good safety profile; not a miracle cure. The Jacob 1999 book title set marketing expectations that the evidence has not fully supported.
Often saidMSM provides energy or stimulant effects.
ActuallyMSM is not a stimulant. The "energy" marketing claims are not supported by trial evidence. Users sometimes report improved general wellbeing through mechanisms that may include reduced joint pain or improved sleep from reduced inflammation.
Often saidMSM eye drops cure cataracts.
ActuallyThe ophthalmic MSM claims (cataracts, floaters, eye health generally) are not supported by clinical evidence. Mainstream ophthalmology has not endorsed routine use.
Who profits, and who pushes back
Mainstream rheumatology
MSM is not incorporated into mainstream osteoarthritis treatment guidelines as routine therapy. Modest symptomatic benefit has been documented in trials, particularly in combination with glucosamine and chondroitin, but effect sizes are smaller than NSAIDs or intra-articular procedures. Reasonable patient choice with good safety profile; not first-line guideline therapy.
Sports medicine literature
The MSM exercise recovery evidence (Pagonis, Withee) is real but modest. The effect sizes are substantially smaller than adequate sleep, appropriate nutrition, training periodization, and recovery time. MSM is reasonable supplemental support; not a substitute for foundational recovery practices.
Allergy and immunology specialty
The Barrager pilot evidence for allergic rhinitis is encouraging but preliminary; larger trials have not consistently replicated the finding. Standard allergic rhinitis treatment (antihistamines, intranasal corticosteroids, immunotherapy) has substantially more robust evidence. MSM is reasonable patient trial; not guideline therapy.
Stanley Jacob
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Career-defining work developing DMSO and MSM at Oregon Health Sciences University. Major commercial interests in the compounds throughout his career. Died 2015; foundational scientific work intermingled with substantial commercial relationships.
Bergstrom Nutrition
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Major commercial backer of MSM clinical research and the dominant premium MSM manufacturer. Funded substantial portions of the modern OptiMSM clinical evidence base. Disclosed industry source.
Sports nutrition industry
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Substantial commercial interest in exercise recovery marketing of MSM. Combined products dominate the consumer category.
Functional medicine community
Long-standing advocates for MSM in joint and inflammatory protocols. Some commercial interests through supplement sales; framing generally measured relative to other supplement categories.
Joint supplement manufacturers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Aggressive direct-to-consumer marketing of MSM in combination joint products. Source disclosure varies, some products use OptiMSM, others use unspecified material.
Veterinary medicine community
Substantial veterinary use of MSM in horses and dogs for joint conditions. Different clinical pathway than human medicine but parallel evidence development.
How we got here
MSM's clinical history begins with DMSO, the precursor compound. Stanley Jacob at Oregon Health Sciences University developed dimethyl sulfoxide for industrial and pharmaceutical use beginning in the 1960s, initially as a vehicle for transdermal drug delivery, then for joint pain (FDA approved DMSO for interstitial cystitis in 1978). Jacob and colleagues observed that DMSO's primary metabolite, MSM, appeared to retain many of DMSO's beneficial effects without the strong garlic-like body odor that limited DMSO's consumer adoption. The Stanford analytical chemistry work of Richmond and colleagues (1986) established MSM as a normal human blood metabolite, providing the pharmacological foundation for supplementation. Commercial MSM supplementation began in 1982 with Stanley Jacob's pioneering work and the founding of companies focused on the compound. Bergstrom Nutrition emerged as the manufacturing leader, developing the distilled (rather than crystallized) production process that produced higher-purity OptiMSM. The 1999 Jacob book "The Miracle of MSM: The Natural Solution for Pain" substantially mainstreamed the supplement to consumer audiences. The 2000s saw expansion into joint health combinations (with glucosamine and chondroitin) and the broader consumer wellness category. The Usha 2004 combination trial, Kim 2006 standalone trial, and Barrager 2002 allergy pilot established the modern evidence base. Pagonis 2014 and Withee 2017 added exercise recovery applications. In the 2010s-2020s the consumer market has been dominated by joint combination formulations, with MSM as the third component alongside glucosamine and chondroitin. The OptiMSM-versus-generic-crystalline quality differential has become more visible in third-party testing reports. The mass-market wellness category has not produced new clinical evidence at the same pace as the early 2000s pioneers; the modern category is largely consolidation around the established indications.
- 1960sStanley Jacob develops DMSO for pharmaceutical use at OHSU
- 1978FDA approves DMSO for interstitial cystitis
- 1982Commercial MSM supplementation begins
- 1985Lawrence/Jacob clinical observations of MSM joint effects
- 1986Richmond Stanford work characterizes MSM as normal blood metabolite
- 1999Jacob publishes "The Miracle of MSM", consumer mainstreaming
- 2002Barrager seasonal allergic rhinitis pilot trial
- 2004Usha glucosamine + MSM combination trial
- 2006Kim standalone knee OA trial
- 2007GRAS status confirmed in US
- 2008Brien safety review consolidates evidence
- 2014Pagonis exercise recovery trial
- 2017Withee resistance training recovery trial
What we do not know
- Why the Usha 2004 combination benefit was substantially larger than the standalone components, whether mechanism is truly additive or whether trial design effects matter.
- Whether the Barrager allergic rhinitis pilot evidence will replicate in larger trials, establishing this indication.
- Whether the exercise recovery effects (Pagonis, Withee) translate to consistent performance benefits across athletic populations and protocols.
- Whether the higher-dose protocols (6g/day) produce proportionally better outcomes than 3g/day, or whether ceiling effects emerge.
- Whether topical MSM preparations have meaningful absorption and tissue-level effects beyond oral.
- Whether OptiMSM clinical superiority over generic crystalline MSM in head-to-head trials would be detectable, currently inferred from trial-evidence patterns rather than direct comparison.
Legal status
Universally available globally as a dietary supplement. GRAS (Generally Recognized As Safe) status in the US since 2007. No regulatory restrictions in any major market. Bergstrom Nutrition (Washington state) dominates the premium MSM market with OptiMSM. Major US consumer brands using OptiMSM include Doctor's Best, Now Foods (in some formulations), Pure Encapsulations, Designs for Health, Thorne. Mass-market joint combination products (Move Free, Osteo Bi-Flex) commonly include MSM, though source disclosure varies, some use OptiMSM, others use unspecified crystalline.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Bergstrom Nutrition (Vancouver, Washington) is the dominant premium MSM manufacturer and the producer of OptiMSM, distilled rather than crystallized, with 99.7% purity and extensive third-party testing. The distillation process removes solvent residues, heavy metals, and other contaminants that may persist in crystallization. Most major joint supplement clinical trials of the past two decades used OptiMSM. Commodity crystalline MSM dominates lower-tier US and global supply; quality is variable and source disclosure is often poor. Chinese-manufactured MSM has historically faced concerns about manufacturing residuals. Premium brands that disclose OptiMSM source represent a meaningful quality differential, particularly for chronic-use protocols.
At a glance
- Structure
- Methylsulfonylmethane / dimethyl sulfone
- Body production
- Endogenous from gut bacteria, hepatic DMSO oxidation
- Dietary intake
- 2-6mg/day from milk, coffee, vegetables
- Standard dose
- 1.5-6g/day
- Joint trial dose
- 3g twice daily
- Exercise recovery dose
- 3g/day for 7-28 days
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about MSM. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
Meta-analysis pooling DMSO and MSM trials concluded neither is clinically effective for osteoarthritis pain
Brien et al., Evidence-Based Complementary and Alternative Medicine (2011)
Debbi 2011 RCT: 49 patients, 3.375 g/day, 12 weeks; significant function benefit (p=0.04), pain trend only (p=0.08), authors call improvements small
Debbi et al., BMC Complementary and Alternative Medicine (2011), PMC3141601
MSM chemistry, dietary sources, pharmacokinetics, NOAEL 1.5 g/kg/day in rats, tolerability up to 4 g/day, GRAS 2007, Kim 2006 and Usha 2004 OA results
Half-marathon RCT: 3 g/day 3 weeks; no reduction in oxidative stress or muscle damage, minor pain attenuation only
Withee et al., Journal of the International Society of Sports Nutrition (2017), PMC5521097
Pilot study: trend toward reduced muscle soreness and fatigue, favoring 3 g/day over 1.5 g/day, antioxidant capacity increase
Consumer safety overview: MSM well tolerated, mild GI side effects, sulfa allergy not a contraindication
MSM uses, gram-level dosing, forms, and cautions with anticoagulants and in renal impairment
OARSI 2019 guideline recommends against glucosamine and chondroitin for knee OA on low-quality-evidence grounds, framing cautious clinical stance on joint supplements
Systematic review of DMSO and MSM in knee OA: both MSM studies reported pain improvement but no definitive conclusion
Meta-analysis, Evidence-Based Complementary and Alternative Medicine (2011), PMC3135791
The studies that matter
Richmond MSM blood detection1986
Stanford analytical chemistry work identifying MSM as a normal blood metabolite in humans and animals, established baseline pharmacology of the compound prior to commercial supplementation.
Lawrence DMSO/MSM joint observations1985
Stanley Jacob and colleagues at OHSU documented joint pain reduction with topical DMSO that persisted with the metabolite MSM, the clinical observation that drove commercial MSM development.
Usha MSM + glucosamine combination trial2004
Indian RCT in knee osteoarthritis: MSM (500mg three times daily) + glucosamine (500mg three times daily) versus either alone. Combination produced greater pain reduction and improved walking time than either component alone over 12 weeks. Foundational combination trial.
Kim MSM knee OA trial2006
Korean placebo-controlled trial: 3g MSM twice daily for 12 weeks in knee osteoarthritis. Significant improvements in WOMAC pain and function scores versus placebo. Among the cleanest standalone MSM joint trials.
Barrager seasonal allergic rhinitis2002
Pilot trial of 2.6g MSM daily for 30 days in seasonal allergic rhinitis: meaningful symptom reduction (respiratory, total symptom load) with low side effect burden. Among the better preliminary evidence for the allergy indication.
Pagonis MSM exercise recovery2014
Greek trial in trained athletes: 3g MSM daily for 10 days prior to half-marathon reduced muscle soreness, fatigue, and post-exercise inflammatory markers (IL-1β, TNF-α). Foundational exercise recovery evidence.
Withee MSM exercise recovery2017
American trial in resistance-trained men: 3g MSM daily for 28 days prior to acute exercise reduced muscle soreness markers. Replication of Pagonis findings in resistance training context.
Brien MSM safety review2008
Comprehensive safety review across human trials: no serious adverse events at doses up to 6g/day. Established the safety profile underlying current dosing guidance.
Notarnicola MSM knee OA review2016
Systematic review of MSM joint trials concluding modest but consistent symptomatic benefit, larger when combined with glucosamine and chondroitin than as standalone.